PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for September 10, 2007 Subscribe to this News Feed    Subscribe to this Podcast Feed
 

New England Peptide Expands Custom Antibody Program

Company conjugates Polyclonal Antibodies to Gold, Biotin.

Gardner, Mass. (PRWEB) September 10, 2007 -- New England Peptide, LLC (NEP), expanding its custom offerings, LLC, is now conjugating polyclonal antibodies to gold and biotin.

"The new conjugation possibilities add to long list of host species and polyclonal protocols that NEP offers," says Dave Robinson, CEO, "and further NEP's goal of providing a full suite of polyclonal antibody services."

"We are committed to meeting customer needs as comprehensively as possible while maintaining the quality and service for which NEP has become known," states Robinson. "Growing the custom antibody program is one key way we can serve our market better."

According to Robinson, NEP has gained a reputation throughout the peptide industry for quality peptides and exceptional customer service - two ingredients necessary for successful custom polyclonal antibodies. The company provides:

 
  • An ELISA success rate of greater than 99 percent;
  • Average ELISA titer of 1:1,100,000;
  • 100 percent guaranteed customer satisfaction.

New England Peptide (www.newenglandpeptide.com) designs and manufactures peptide and antibody products for drug discovery organizations worldwide. Headquartered in Gardner, Mass., and founded in 1998, the company specializes in custom peptide synthesis and polyclonal antibody production.

###

OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Aimee Bennett
New England Peptide
303-843-9840
Email us Here
ATTACHED FILES

Press Release Attachment

Press Release Attachment

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.